CoChat
Sign Up
Cited by 5

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Surface LDLR is a major receptor for lipoprotein(a) clearance in male mice lacking PCSK9

Roubtsova, Anna, Scipione, Corey A., Garçon, Damien, Boffa, Michael B., Seidah, Nabil G., Koschinsky, Marlys L., Prat, Annik·2023·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
DOI 10.1016/j.bbalip.2023.159288
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbalip.2023.159288

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 15

  1. Pare, 2019, Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups, Circulation, 139, 1472, 10.1161/CIRCULATIONAHA.118.034311 · DOI
  2. McKenney, 2012, Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy, J. Am. Coll. Cardiol., 59, 2344, 10.1016/j.jacc.2012.03.007 · DOI
  3. Raal, 2014, Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials, J. Am. Coll. Cardiol., 63, 1278, 10.1016/j.jacc.2014.01.006 · DOI
  4. Seidah, 2022, The multifaceted biology of PCSK9, Endocr. Rev., 43, 558, 10.1210/endrev/bnab035 · DOI · Paper page
  5. Zaid, 2008, Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration, Hepatology, 48, 646, 10.1002/hep.22354 · DOI · Paper page
  6. Romagnuolo, 2015, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor, J. Biol. Chem., 290, 11649, 10.1074/jbc.M114.611988 · DOI · Paper page
  7. Romagnuolo, 2017, Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9, PLoS ONE, 12, 10.1371/journal.pone.0180869 · DOI
  8. Koschinsky, 1991, Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells, Biochemistry, 30, 5044, 10.1021/bi00234a029 · DOI
  9. Roubtsova, 2015, PCSK9 deficiency unmasks a sex/tissue-specific subcellular distribution of the LDL and VLDL receptors in mice, J. Lipid Res., 56, 2133, 10.1194/jlr.M061952 · DOI · Paper page
  10. Cain, 2005, Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a], J. Lipid Res., 46, 2681, 10.1194/jlr.M500249-JLR200 · DOI · Paper page
  11. Hofmann, 1990, Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice, J. Clin. Invest., 85, 1542, 10.1172/JCI114602 · DOI · Paper page
  12. Reyes-Soffer, 2017, Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans, Circulation, 135, 352, 10.1161/CIRCULATIONAHA.116.025253 · DOI · Paper page
  13. Ying, 2022, PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration, J. Intern. Med., 291, 870, 10.1111/joim.13457 · DOI
  14. Cordero, 2022, Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: the LIPID-REAL registry, J. Cardiovasc. Pharmacol., 79, 523, 10.1097/FJC.0000000000001205 · DOI
  15. Sever, 2021, LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial, Eur. J. Prev. Cardiol., 28, 805, 10.1177/2047487320902750 · DOI

Cited by

Sorted by citations

Metadata

Authors
Roubtsova, A., Scipione, C. A., Garçon, D., Boffa, M. B., Seidah, N. G., Koschinsky, M. L., & Prat, A.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Publisher
Elsevier BV
Published
2023-04
Volume
1868
Issue
4
Pages
159288
ISSN
1388-1981
DOI
10.1016/j.bbalip.2023.159288
Cited by
5
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review